The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo

Table 1 PCGEM1 -associated expression signature in PCa patient samples

Concept	Studies (Up/Down)	P-value	Odds ratio	Total samples
PCa vs. Other Neoplasms	1/0	4.44E-15	30.9	1468
PCa vs. Normal Prostate	5/0	1.88E-10 - 2.00E-03	14.5 - 4.5	299
Metastatic PCa vs. Primary PCa	0/6	6.69E-13 - 5.00E-03	27.0 - 4.5	448
High Gleason PCa vs. Low Gleason PCa	0/5	8.01E-11 - 6.00E-3	16.8 - 5.0	676
Hormone-Refractory PCa vs. Hormone-naïve PCa	0/1	4.74E-05	9.6	20
Clinical Outcomes
Reoccurrence at 3 or 5 years	0/2	1.45E-06 - 4.52E-04	8.4 - 5.1	168
Dead at 3 or 5 years	0/2	4.65E-07 - 9.02E-04	20.6 -7.8	721

The MSKCC database was queried using cBioPortal for genes that are co-expressed with PCGEM1 (Pearson’s Correlation > 0.50), which were then uploaded into the Oncomine database (thresholds: p-value < 0.01, odds ratio > 2). Only clinically-related Oncomine concepts were analyzed and are listed in the first column. Here, PCGEM1 expression in PCa was compared to 15 other neoplasms. The second column summarizes the total number of independent studies showing either up- or down-regulation of PES for the corresponding concept. “Total Samples” reflect the grand total of number of patients in every study that met the threshold for the corresponding concept. Oncomine (Compendia Bioscience) was used for statistical analysis.

ISSN: 1476-4598